Office of Community Engagement
Mission of the Center for Compassionate Care Innovation
The Department of Veterans Affairs (VA) provides a wide array of state-of-the-art treatments, evidence-based therapies and is a leader in research and innovation. VA is committed to providing the best healthcare available to Veterans and is interested in learning about new treatment modalities used in the private sector that result in positive health outcomes.
The Center for Compassionate Care Innovation (CCI) is a program within the Office of Community Engagement (OCE). The mission of CCI is to explore emerging therapies that are safe and ethical to enhance Veteran physical and mental well-being when other treatments have not been successful. CCI focuses on the conditions below and others that may be resistant to standard treatments:
Given that there may be numerous innovative treatment approaches for each of the above conditions, CCI is tasked with prioritizing proposals that have a current or emerging evidence-base documenting their efficacy, are cleared by the Food and Drug Administration (FDA) for their intended purpose, and are designed to offer sustained benefits to the target population. CCI has a thorough and thoughtful review process in order to identify proposals that are appropriate for implementation. Proposals shared with CCI should be aligned with CCI’s mission, not already available within the VHA network, feasible to implement, and developed in accordance with CCI’s guidelines.
The Center for Compassionate Care Innovation Will:
- Maintain integrity of the fundamental principle to “Do No Harm.”
- Evaluate emerging modalities, devices, and interventions that are safe and ethical in order to augment and support current VHA evidence-based program.
- Advocate for shared decision-making where Veterans are active participants in choosing treatments, interventions, or therapies.
- Examine innovative proposals that may provide help and hope to Veterans who have not responded to standard treatments.
- Collaborate with experts across healthcare disciplines to consider noteworthy, safe, and ethical emerging therapies that are not currently in widespread clinical use in VA.